Awarded
Additional PF-07321332 Supply Agreement for Pandemic Purposes
£1
goods
Contract Details
- Tender Value
- £1
- Stage
- Awarded
- Published
- Awarded
Timeline
Awarded
Start
Disclosed
End
Description
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. This agreement is for the procurement of 2,500,000 units of PF-07321332/ritonavir. It is one of the first oral and direct-acting antiviral drugs globally and is part of the UK's multi-layered approach to COVID-19.
Related Contracts
From This Buyer
- DHSC: MR General legal services
£50,000 ·
- DHSC: UKHSA Chair campaign
£26,000 ·
- EBSCO Discovery Services (EDS) Tool
£21,233 ·
- DHSC: Fin: Interim Senior Financial Accountant
£94,250 ·
From This Supplier
- TERMS AND CONDITIONS FOR THE SUPPLY OF CENTRALLY PROCURED VACCINES
£1 ·
- PF-07321332 Supply Agreement for Pandemic Purposes
£1 ·
- Terms and Conditions for the Supply of Centrally Procured Vaccines - SARS-CoV-2 VACCINE SUPPLY AGREEMENT
£1 ·
- TERMS AND CONDITIONS FOR THE SUPPLY OF CENTRALLY PROCURED VACCINES
£1 ·
In This Category
- Twilio SMS Authentication
£99,999 ·
- Award of Conductive Energy Devices and Associated Equipment
£1,764,041 ·
- WSFT - Capital Purchase - IT - Dell laptops
£500,000 ·
- Provision of Office Supplies
£32,000,000 ·
Ref: 41d774d8-4e46-4812-bf15-989885e81077-501647 · Sourced from Contracts Finder
View source notice